Self-delivering RNAi immunotherapeutic PH-762 silences PD-1 to generate local and abscopal antitumor efficacy
2024

Self-delivering RNAi Immunotherapy PH-762 Silences PD-1 for Antitumor Efficacy

publication Evidence: moderate

Author Information

Author(s): Cuiffo Benjamin, Maxwell Melissa, Yan Dingxue, Guemiri Ramdane, Boone Andrew, Bellet Deborah, Rivest Brianna, Cardia James, Robert Caroline, Fricker Simon P.

Primary Institution: Phio Pharmaceuticals

Hypothesis

Can PH-762, a self-delivering RNAi therapeutic, effectively silence PD-1 to enhance antitumor immunity?

Conclusion

PH-762 shows promise as a neoadjuvant immunotherapy candidate by effectively silencing PD-1 and generating both local and systemic antitumor effects.

Supporting Evidence

  • PH-762 was rapidly internalized by human T cells, silencing PD-1 mRNA and decreasing PD-1 surface protein.
  • IT mPH-762 provided robust antitumor efficacy and was well tolerated in murine models.
  • IT mPH-762 demonstrated efficacy against untreated distal tumors, indicating an abscopal effect.

Takeaway

This study tested a new treatment that helps the immune system fight cancer by turning off a protein called PD-1, which can stop immune cells from working.

Methodology

The study involved in vitro and in vivo experiments using murine tumor models to evaluate the pharmacology and antitumor efficacy of PH-762.

Limitations

The study is preclinical and results may not directly translate to human patients.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1501679

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication